Group 1 - The company Qianjiang Biochemical (600796.SH) has announced the completion and operation of its 1.2MWp photovoltaic project under Hongcheng Environmental Protection, in addition to the 3.5MWp project at Changhe Waterworks [1] - The 3.5MWp distributed photovoltaic project at Changhe Waterworks is expected to generate an annual output of 4 million kWh, saving over 10 million yuan in electricity costs over a 20-year period [3] - The company is planning additional photovoltaic projects, with a 0.8MWp project at the Hangzhou Bay New Area sewage treatment plant expected to be completed by the end of the year [1]

Core Viewpoint - Qianjiang Biochemical (600796.SH) has successfully launched multiple photovoltaic power generation projects, contributing to cost savings and environmental sustainability [1] Group 1: Project Developments - The Changhe Water Affairs 3.5MWp photovoltaic power generation project was completed and operational in March this year [1] - The project has saved 280,000 yuan in electricity costs over four months since its operation [1] - The Hongcheng Environmental 1.2MWp photovoltaic power generation project has also been completed and is operational [1] - An additional 0.8MWp photovoltaic project, associated with the new sewage treatment plant in Hangzhou Bay New Area, is expected to be completed by the end of this year [1]

Core Viewpoint - Qianjiang Biochemical (600796.SH) has successfully launched multiple photovoltaic power generation projects, contributing to cost savings and future project developments [1] Group 1: Project Developments - Changhe Water's 3.5MWp photovoltaic power generation project was completed and operational in March this year, resulting in electricity cost savings of 280,000 yuan over four months [1] - Hongcheng Environmental's 1.2MWp photovoltaic power generation project has also been completed and is now operational [1] - The 0.8MWp photovoltaic project associated with the new sewage treatment plant in Hangzhou Bay New Area is expected to be completed by the end of this year [1]

Core Viewpoint - The company, Zhejiang Qianjiang Biochemical Co., Ltd., is set to hold a third-quarter performance briefing on November 18, 2025, to discuss its operational results and financial status for the third quarter of 2025, allowing investors to engage in a Q&A session [2][3]. Group 1: Meeting Details - The performance briefing will take place on November 18, 2025, from 10:00 to 11:00 AM [4]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [4][5]. - Investors can submit questions from November 11 to November 17, 2025, through the Roadshow Center's website or via the company's email [2][5]. Group 2: Participants - Key participants in the briefing will include the Chairman and General Manager Zhu Yangang, Board Secretary Lu Pingyan, Chief Financial Officer Ma Yuezhong, and Independent Director Wang Lida [4]. Group 3: Investor Participation - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [4][5]. - The company will address commonly asked questions during the session, ensuring transparency and engagement with investors [3][5]. Group 4: Contact Information - For inquiries, investors can contact the Securities Legal Affairs Department via phone or email [5].

浙江钱江生物化学股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 证券代码：600796 证券简称：钱江生化 公告编号：临 2025-054 （一）会议召开时间：2025年11月18日（星期二）10:00-11:00 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 11 日 （星期二） 至 11 月 17 日 （星 期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 qjbioch@600796.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 浙江钱江生物化学股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 18 日 （星期二） 10:00-1 ...

Core Viewpoint - The company is actively involved in the "Vanguard" and "Leading Goose" projects in Zhejiang Province, focusing on the development and application of plant growth-promoting bacteria and related stimulants, which aims to enhance soil improvement and profitability [1] Group 1 - The project aims to develop plant growth-promoting bacteria products for soil improvement, expanding the company's product offerings into the soil enhancement sector [1] - The company has completed the development of a high-concentration gibberellic acid soluble agent and one microbial agent, with samples delivered [1] - The microbial fertilizer has entered the registration process, with an expected registration certificate by 2026 [1]

Group 1 - The core viewpoint of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant advancement in biotechnology and organ transplantation [1] - The first clinical trial was completed at NYU Langone Medical Center, approved by the FDA, aiming to evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - Global advancements in gene editing technology have been reported, including successful transplantation of gene-edited pig lungs in China and new treatment approaches for Down syndrome in Japan [1] Group 2 - Huazhong Securities highlights that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production of drugs [2] - In the A-share market, there are 22 listed companies with gene editing technology reserves, with mixed performance in stock prices; only 7 out of 22 companies saw gains on November 5 [4] - Among gene editing concept stocks, Shuanglu Pharmaceutical reported the highest net profit of 141 million yuan in the first three quarters, while Mengcao Ecological achieved a year-on-year profit increase of 48.73% [5][6] Group 3 - Eight gene editing concept stocks received attention from five or more institutions, with companies like Sturdy Medical and Huaxi Biological leading in institutional ratings [7] - Sturdy Medical announced a collaboration with Huazhong Agricultural University to establish a cotton research institute, focusing on gene editing and hybridization techniques for cotton seed improvement [7]

Group 1 - The core point of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant breakthrough in gene editing technology [1] - The trials are approved by the FDA and aim to systematically evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - There have been multiple advancements in gene editing technology globally, including successful transplants of gene-edited organs and new treatment approaches for genetic disorders [1] Group 2 - Huazhong Securities notes that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production and reducing drug production costs [2] - A total of 22 listed companies in the A-share market have gene editing technology reserves, with several companies reporting profitability in their third-quarter results [3] - Notable companies include Shuanglu Pharmaceutical, which reported a net profit of 141 million yuan, and Mengcao Ecological, which saw a 48.73% year-on-year increase in net profit [3][4] Group 3 - Companies like Wanjian Medical are collaborating with research institutions to develop cotton varieties using gene editing technology, indicating the application of gene editing beyond human health [5] - The number of institutional ratings for gene editing concept stocks shows significant interest, with companies like Wanjian Medical and Huaxi Biological receiving the highest number of ratings [6]

Core Insights - The environmental governance sector saw an increase of 0.81% on November 3, with Zhejiang Fu Holdings leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Environmental Governance Sector Performance - Top gainers included: - Zhejiang Fu Holdings (002266) with a closing price of 4.52, up 9.98% and a trading volume of 1.93 million shares, totaling 873 million yuan [1] - Zhonghuan Environmental (300692) at 9.58, up 7.28% with a trading volume of 450,900 shares, totaling 434 million yuan [1] - Haitan Co., Ltd. (603759) at 11.74, up 6.73% with a trading volume of 370,700 shares, totaling 413 million yuan [1] - Other notable gainers included: - Feima International (002210) at 4.45, up 5.95% with a trading volume of 6.29 million shares, totaling 2.83 billion yuan [1] - ST New Power (300152) at 2.50, up 5.49% with a trading volume of 374,000 shares, totaling 9.19 million yuan [1] Fund Flow Analysis - The environmental governance sector experienced a net outflow of 772 million yuan from institutional investors, while retail investors saw a net inflow of 677 million yuan [2] - The top stocks by fund flow included: - Zhejiang Fu Holdings (002266) with a net inflow of 22.3 million yuan from institutional investors, but a net outflow of 114 million yuan from speculative funds [3] - Feima International (002210) with a net inflow of 10.7 million yuan from institutional investors, but a net outflow of 97.8 million yuan from speculative funds [3] - Yuan Da Environmental (600292) with a net inflow of 38.3 million yuan from institutional investors, but a net outflow of 14.9 million yuan from speculative funds [3]

特此公告。 浙江钱江生物化学股份有限公司董事会 2025 年 11 月 1 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江钱江生物化学股份有限公司（以下简称"公司"）工会联合会委员会于 近日召开了 2025 年第二次代表大会，审议并通过《关于监事会不再设立后职工 监事不再任职的议案》。根据《中华人民共和国公司法》、中国证券监督管理委 员会《关于新<公司法>配套制度规则实施相关过渡期安排》《公司章程》等法律 法规、监管制度的相关要求，结合公司实际情况，公司不再设立监事会，现任职 工监事朱炳其先生自监事会正式撤销之日起不再担任职工监事。上述调整自公司 《关于增加经营范围、取消监事会并修订<公司章程>的议案》经公司股东大会审 议通过后生效。 证券代码：600796 股票简称：钱江生化 编号：临 2025—053 浙江钱江生物化学股份有限公司 关于监事会不再设立后职工监事不再任职的公告 ...